No More “Wait and See”: Two Clinical Trials Target the Origins of Recurrent Ovarian Cancer
News Release For Immediate Release Media Contact: Kari McHugh Kari.McHugh@breakthroughcancer.org No More “Wait and See”: Two Clinical Trials Target the Origins of Recurrent Ovarian Cancer Break Through Cancer scientists are evaluating a “second-look” technique to measure and destroy persistent cancer cells resistant to frontline chemotherapy. (CAMBRIDGE, MASS.) September 26, 2024 – After initial therapy to treat ovarian cancer, a small number of cancer cells, undetectable on scans, often linger in the body. These cells, referred to as minimal residual disease (MRD), are the seed from which cancer can and does recur for most women diagnosed with stage III or......